Journal Mobile Options
Table of Contents
Vol. 75, No. 1, 2011
Issue release date: January 2011
Horm Res Paediatr 2011;75:38–46
(DOI:10.1159/000317529)

Prospective Study Confirms Oxandrolone-Associated Improvement in Height in Growth Hormone-Treated Adolescent Girls with Turner Syndrome

Zeger M.P.D. · Shah K. · Kowal K. · Cutler, Jr. G.B. · Kushner H. · Ross J.L.
aDepartment of Pediatrics, Thomas Jefferson University, Philadelphia, Pa., bDepartment of Pediatrics, duPont Hospital for Children (Nemours), Wilmington, Del., cDevelopmental Endocrinology Branch, NIH/NICHD, Bethesda, Md., and dBiomedical Computer Research Institute, Philadelphia, Pa., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Untreated girls with Turner syndrome (TS) have growth failure, and adult height is, on average, 20 cm less than predicted height. Treatment with growth hormone (GH) is now standard of care. The objective of this study was to investigate the benefit of adding oxandrolone (Ox) to GH in a long-term, randomized, placebo (Pl)-controlled prospective trial to near adult height in TS. Methods: Prospective, randomized, Pl-controlled study: 76 girls with TS (ages 10–14.9 years) were randomized to receive Ox (0.06 mg/kg/day) or Pl in combination with GH (0.35 mg/kg/week, daily) over 2 years. Auxologic data, breast and pubic hair Tanner stages, and hormone and lipid levels were measured. Subjects who chose to continue were followed in a 2-year double-blind extension, also received estrogen therapy (years 3, 4), and had dual-energy X-ray absorptiometry evaluation of bone density (years 3, 4). Results: At year 4, the change in absolute height and height SDS was greater in the GH/Ox versus GH/Pl group [26.2 ± 6.7 vs. 22.2 ± 5.1 cm, analysis of covariance (ANCOVA) p < 0.001; 1.8 ± 0.9 vs. 1.2 ± 0.7 standard deviation scores, ANCOVA p < 0.001]. Bone mineral density (BMD) of the wrist (0.51 ± 0.17 vs. 0.54 ± 0.05 g/cm2) and spine (0.91 ± 0.34 vs. 0.96 ± 0.13 g/cm2) in the GH/Ox versus GH/Pl groups was similar after 4 years. Breast development was slower in the GH/Ox versus GH/Pl group [year 4: Tanner stage 2.9 ±1.3 (Ox) vs. 4.1 ± 1.3 (Pl), p = 0.003], and menarche was approximately 1 year later. Conclusions: The addition of Ox to GH at mean age 12.0 ± 1.7 year augmented height gain after 4 years of treatment, slowed breast development and did not affect BMD in girls with TS. Whether initiation of Ox prior to initiation of pubertal development would optimize height gain without impeding breast development will require further study.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Lyon AJ, Preece MA, Grant DB: Growth curve for girls with Turner syndrome. Arch Dis Child 1985;60:932–935.
  2. Bareille P, Massarano AA, Stanhope R: Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. Eur J Pediatr 1997;156:358–362.
  3. Crock P, Werther GA, Wettenhall HN: Oxandrolone increases final height in Turner syndrome. J Paediatr Child Health 1990;26:221–224.
  4. Bondy CA: Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007;92:10–25.
  5. Urban MD, Lee PA, Dorst JP, Plotnick LP, Migeon CJ: Oxandrolone therapy in patients with Turner syndrome. J Pediatr 1979;94:823–827.
  6. Joss E, Zuppinger K: Oxandrolone in girls with Turner’s syndrome: a pair-matched controlled study up to final height. Acta Paediatr Scand 1984;73:674–679.
  7. Naeraa RW, Nielsen J, Pedersen IL, Sorensen K: Effect of oxandrolone on growth and final height in Turner’s syndrome. Acta Paediatr Scand 1990;79:784–789.
  8. Rosenbloom AL, Frias JL: Oxandrolone for growth promotion in Turner syndrome. Am J Dis Child 1973;125:385–387.
  9. Menke LA, Sas TC, de Muinck Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ, et al: Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2010;95:1151–1160.
  10. Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hagenas L, et al: Improved final height in girls with Turner’s syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996;81:635–640.
  11. Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, et al: Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr 1998;132:319–324.
  12. Stahnke N, Keller E, Landy H: Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. J Pediatr Endocrinol Metab 2002;15:129–138.
  13. Rochiccioli P, Battin J, Bertrand AM, Bost M, Cabrol S, le Bouc Y, et al: Final height in Turner syndrome patients treated with growth hormone. Horm Res 1995;44:172–176.
  14. Joss EE, Mullis PE, Werder EA, Partsch CJ, Sippell WG: Growth promotion and Turner-specific bone age after therapy with growth hormone and in combination with oxandrolone: when should therapy be started in Turner syndrome? Horm Res 1997;47:102–109.
  15. Cacciari E, Mazzanti L: Final height of patients with Turner’s syndrome treated with growth hormone (GH): indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner Syndrome. J Clin Endocrinol Metab 1999;84:4510–4515.
  16. Bakalov VK, Shawker T, Ceniceros I, Bondy CA: Uterine development in Turner syndrome. J Pediatr 2007;151:528–531.
  17. Ross JL, Long LM, Feuillan P, Cassorla F, Cutler GB Jr: Normal bone density of the wrist and spine and increased wrist fractures in girls with Turner’s syndrome. J Clin Endocrinol Metab 1991;73:355–359.
  18. Davis SR, Burger HG: Clinical review 82: androgens and the postmenopausal woman. J Clin Endocrinol Metab 1996;81:2759–2763.
  19. Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist. Stanford, Stanford University Press, 1959.
  20. Sawyer AB, Bachrach LK, Fung EB: Bone Densitometry in Growing Patients: Guidelines for Clinical Practice. Totowa, Humana Press, 2007.
  21. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al: CDC growth charts: United States. Adv Data 2000;314:1–27.

    External Resources

  22. Carel JC, Ecosse E, Bastie-Sigeac I, Cabrol S, Tauber M, Leger J, et al: Quality of life determinants in young women with Turner’s syndrome after growth hormone treatment: results of the StaTur population-based cohort study. J Clin Endocrinol Metab 2005;90:1992–1997.
  23. Johanson AJ, Blizzarrm BJ: Growth in patients with gonadal dysgenesis receiving fluoxymesterone. J Pediatr 1969;75:1015–1021.
  24. Doerr HG, Bettendorf M, Hauffa BP, Mehls O, Partsch CJ, Said E, et al: Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: results of the German IGLU Follow-Up Study 2001. Hum Reprod 2005;20:1418–1421.
  25. Dimitrakakis CZJ, Wang J, Belanger A, La Brie F, Cheng C, Powell D, Bondy C: A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292–298.
  26. Raisz L, Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M, Shoukri K, Smith J: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996;81:37–43.
  27. Han T, Cadge B, Conway GS: Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner’s syndrome. Clin Endocrinol (Oxf) 2006;65:643–647.
  28. Ross JL, Mazzocco MM, Kushner H, Kowal K, Cutler GB Jr, Roeltgen D: Effects of treatment with oxandrolone for 4 years on the frequency of severe arithmetic learning disability in girls with Turner syndrome. J Pediatr 2009;155:714–720.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50